Eledon asset shows optimistic biomarker activity in ALS trialR&D, TherapeuticsOn Tuesday morning, Eledon Pharmaceuticals announced positive topline results from the company’s Phase IIa clinical trial evaluating tegoprubart in patients with amyotrophic lateral sclerosis (ALS). Read more May 31, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/BioSpacewheelchair5-31-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-05-31 12:16:202022-05-31 12:23:31Eledon asset shows optimistic biomarker activity in ALS trial